Evidence map›Paper›PMID 29967538›Full record

ArticleNature structural & molecular biology2018

Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein.

Maria Victoria Botuyan, Gaofeng Cui, Pascal Drané, Catarina Oliveira, Alexandre Detappe, Marie Eve Brault, Nishita Parnandi, Shweta Chaubey, James R Thompson, Benoît Bragantini and 4 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Maria Victoria BotuyanDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Gaofeng CuiDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Pascal DranéDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catarina OliveiraGenome Integrity Laboratory, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-9060-5112
Alexandre DetappeDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9364-1621
Marie Eve BraultDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nishita ParnandiDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shweta ChaubeyDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
James R ThompsonDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Benoît BragantiniDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5409-2938
Debiao ZhaoDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
J Ross ChapmanGenome Integrity Laboratory, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-6477-4254
Dipanjan ChowdhuryDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. dipanjan_chowdhury@dfci.harvard.edu.ORCID 0000-0001-5645-3752
Georges MerDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. mer.georges@mayo.edu.ORCID 0000-0002-1900-1578
Dana-Farber Cancer Institute · USMayo Clinic in Arizona · USCentre for Human Genetics · GBBroad Institute · USMayo Clinic · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Structural Biology of Lysine Methylation in DNA Damage and Checkpoint SignalingR01CA132878 · NCI · MAYO CLINIC ROCHESTER · PI Georges Mer · 2008 to 2026
$4.5M
Molecular mechanism and relevance of microRNAs in DSB repair pathway choiceR01CA142698 · NCI · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2010 to 2019
$3.8M
Investigating 53BP1 'dephosphorylation' as a critical determinant of PARPR01CA208244 · NCI · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2017 to 2021
$1.9M
Structural basis of RNF168-mediated ubiquitin signaling at chromosomal DNA breaksR01GM116829 · NIGMS · MAYO CLINIC ROCHESTER · PI MER, GEORGES · 2015 to 2018
$1.3M
Cancer Research UK 19270Medical Research Council MR/R017549/1NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA132878NCI NIH HHS R01 CA142698NCI NIH HHS R01 CA208244NIGMS NIH HHS R01 GM116829
6 · The paper itself

Abstract

Dynamic protein interaction networks such as DNA double-strand break (DSB) signaling are modulated by post-translational modifications. The DNA repair factor 53BP1 is a rare example of a protein whose post-translational modification-binding function can be switched on and off. 53BP1 is recruited to DSBs by recognizing histone lysine methylation within chromatin, an activity directly inhibited by the 53BP1-binding protein TIRR. X-ray crystal structures of TIRR and a designer protein bound to 53BP1 now reveal a unique regulatory mechanism in which an intricate binding area centered on an essential TIRR arginine residue blocks the methylated-chromatin-binding surface of 53BP1. A 53BP1 separation-of-function mutation that abolishes TIRR-mediated regulation in cells renders 53BP1 hyperactive in response to DSBs, highlighting the key inhibitory function of TIRR. This 53BP1 inhibition is relieved by TIRR-interacting RNA molecules, providing proof-of-principle of RNA-triggered 53BP1 recruitment to DSBs.

Indexed as

Amino Acid SubstitutionBinding SitesCarrier ProteinsCrystallography, X-RayDNA Breaks, Double-StrandedDNA RepairHistonesHumansModels, MolecularMutagenesis, Site-DirectedProtein BindingProtein EngineeringProtein Interaction MapsProtein Processing, Post-TranslationalPyrophosphatasesRNA-Binding ProteinsCarrier ProteinsHistonesNUDT16L1 protein, humanNudt16 protein, humanPyrophosphatasesRNA-Binding ProteinsTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1

Identifiers

PMID29967538
PMCPMC6045459
OpenAlexW2810589479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.